ReviewEndocrine2021
Assessing the health-related management of people with differences of sex development.
Review in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Management of andrological disorders from childhood and adolescence to transition age: guidelines from the Italian Society of Andrology and Sexual Medicine (SIAMS) in collaboration with the Italian Society for Pediatric Endocrinology and Diabetology (SIEDP) - part-2.Journal of endocrinological investigation · 2026Article
- European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.Orphanet journal of rare diseases · 2026Review
- Clinical features and genetic characteristics of ovotesticular disorders of sex development: 24 cases from a single center.World journal of urology · 2025Article
- The gender incongruence module in the European Registries for Rare Endocrine & Bone Conditions (EuRREB): first results, current insights, and future directions.Endocrine connections · 2025Article
- Development of Quality Indicators to Evaluate the Quality of Care for People with Differences of Sex Development.Hormone research in paediatrics · 2025Article
- Extensive Literature Review of 46,XX Newborns with Congenital Adrenal Hyperplasia and Severe Genital Masculinization: Should They Be Assigned and Reared Male?Journal of clinical research in pediatric endocrinology · 2024Review
- Contexts of care for people with differences of sex development: Diversity is still missing in the laboratory routine.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Differences in Sex Development (DSD) and related conditions: mechanisms, prevalences and changing practice.International journal of impotence research · 2023Review
- Cohort profile: pathways to care among people with disorders of sex development (DSD).BMJ open · 2022Article
- Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care.The lancet. Diabetes & endocrinology · 2022Article
- "Good practices" in pediatric clinical care for disorders/differences of sex development.Endocrine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHealth care requirements and perception of people with differences of sex development (DSD) have changed enormously since the "Chicago Consensus Conference" in 2005. Therefore, new standards of care and evaluation of care have to be developed.
methodsWe summarize the social and legal approach to care for DSD during the last two decades and report the main results of European research activities.
resultsThe last two decades were accompanied by legal and societal discussion regarding how to deal with a nonbinary concept of sex. This leads to the necessity to assess health care requirements for individuals with DSD in an objective manner. We briefly review the results of the recently funded European research projects dealing with health-related issues in DSD like EU COST Action DSD, I-DSD, and dsd-LIFE, and address the compilation of quality indicators that will be needed to benchmark health care provision and health care-related outcomes.
conclusionsThe benchmarking process has to be implemented among health care providers for individuals with DSD within the European Reference Networks for Rare Conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.